TriSalus Life Sciences, Inc. (TLSI)
For informational purposes only. Not financial advice.
TriSalus Life Sciences, Inc. (TLSI) is a publicly traded company trading at $6.11 with a market cap of 201860940. It holds a moderate AI score of 65/100 based on fundamental, technical, and sentiment analysis.
TriSalus Life Sciences, Inc. is an immunotherapy company focused on developing and commercializing treatments for liver and pancreatic tumors. Their innovative approach involves pressure-enabled drug delivery to enhance the effectiveness of immunotherapies.
Company Overview
TriSalus Life Sciences pioneers a novel approach to cancer treatment, focusing on liver and pancreatic tumors through pressure-enabled drug delivery. With innovative systems like TriNav and SD-101, they aim to improve outcomes and address unmet needs in challenging oncology markets, positioning them for significant growth.
Investment Thesis
Investing in TriSalus Life Sciences presents a compelling opportunity due to its innovative approach to treating liver and pancreatic tumors. The company's pressure-enabled drug delivery technology, exemplified by the TriNav Infusion System and SD-101, has the potential to significantly improve therapeutic outcomes in these challenging cancers. A key value driver is the potential market for SD-101 across multiple indications, including hepatocellular carcinoma and pancreatic ductal adenocarcinoma. With a gross margin of 84.0%, TriSalus demonstrates strong potential for profitability as it scales its commercial operations. Upcoming clinical trial results for SD-101 will serve as a major catalyst, potentially validating the efficacy of its technology and driving significant stock appreciation. The company's current market cap of $0.16B offers an attractive entry point, considering the potential for revenue growth and market expansion.
Key Highlights
- Gross margin of 84.0% indicates strong pricing power and efficient cost management in the production and delivery of its specialized infusion systems.
- Market Cap of $0.16B presents a potential undervaluation, offering investors an opportunity to capitalize on future growth and clinical trial successes.
- Focus on liver and pancreatic tumors addresses a significant unmet medical need, positioning TriSalus for growth in a specialized oncology market.
- SD-101, an investigational immunotherapeutic, has the potential to expand treatment options across multiple cancer types, driving future revenue growth.
- Beta of 0.42 suggests lower volatility compared to the overall market, potentially offering a more stable investment within the biotechnology sector.
Competitors
Strengths
- Innovative pressure-enabled drug delivery technology.
- Targeted therapies for difficult-to-treat liver and pancreatic cancers.
- Strong gross margin of 84.0%.
- Proprietary systems like TriNav and SD-101.
Weaknesses
- Limited commercialization experience.
- Reliance on clinical trial success for SD-101.
- Negative P/E ratio of -5.17 indicates current lack of profitability.
- Relatively small market capitalization of $0.16B.
Catalysts
- Upcoming: Clinical trial results for SD-101 in hepatocellular carcinoma.
- Upcoming: Regulatory submissions for SD-101 in additional cancer indications.
- Ongoing: Increasing adoption of TriNav Infusion System in cancer centers.
- Ongoing: Strategic partnerships with pharmaceutical companies to co-develop therapies.
Risks
- Potential: Failure in clinical trials for SD-101, leading to delays or termination of development.
- Potential: Competition from established pharmaceutical companies with greater resources.
- Potential: Regulatory hurdles and delays in obtaining approvals for new therapies.
- Ongoing: Dependence on key personnel and intellectual property.
- Ongoing: Negative profit margin of -98.4% indicates financial instability.
Growth Opportunities
- Expansion of SD-101 into new indications: SD-101 is currently being investigated for various liver and pancreatic cancers. Positive clinical trial results could lead to regulatory approvals and commercialization in additional indications, expanding the addressable market and driving revenue growth. The market for hepatocellular carcinoma therapeutics alone is projected to reach $3.5 billion by 2028, offering a substantial opportunity for TriSalus.
- Increased adoption of TriNav Infusion System: The TriNav Infusion System is already available for hepatic arterial infusion of liver tumors. Increasing awareness and adoption of this system among oncologists could drive revenue growth. This system offers a unique approach to drug delivery, potentially improving treatment outcomes and attracting a larger customer base. Market analysis indicates a growing demand for targeted drug delivery systems in oncology.
- Strategic partnerships with pharmaceutical companies: Collaborating with pharmaceutical companies to co-develop and commercialize SD-101 or other therapies could accelerate development timelines and expand market reach. Partnerships could provide access to additional funding, expertise, and distribution channels, enhancing TriSalus's competitive position. The pharmaceutical industry is actively seeking innovative technologies to improve cancer treatment outcomes.
- Geographic expansion into international markets: Currently focused in the United States, TriSalus has the opportunity to expand its operations into international markets, such as Europe and Asia, where liver and pancreatic cancers are prevalent. This expansion would require regulatory approvals and strategic partnerships, but could significantly increase the company's revenue potential. The global market for cancer therapies is growing rapidly, particularly in emerging economies.
- Development of next-generation drug delivery systems: Investing in research and development to create new and improved drug delivery systems could provide a competitive advantage and drive future growth. This could involve exploring new technologies, such as nanoparticles or microfluidic devices, to further enhance drug penetration and efficacy. Innovation in drug delivery is a key area of focus in the pharmaceutical and biotechnology industries.
Opportunities
- Expansion of SD-101 into new cancer indications.
- Strategic partnerships with pharmaceutical companies.
- Geographic expansion into international markets.
- Increased adoption of TriNav Infusion System.
Threats
- Competition from established pharmaceutical and biotechnology companies.
- Regulatory hurdles and potential delays in clinical trials.
- Potential for failure in clinical trials for SD-101.
- Changes in healthcare reimbursement policies.
Competitive Advantages
- Proprietary pressure-enabled drug delivery technology that enhances drug penetration and efficacy.
- Patent protection for its TriNav Infusion System, Pancreatic Retrograde Venous Infusion System, and SD-101.
- First-mover advantage in developing targeted therapies for liver and pancreatic tumors.
- Strong relationships with key opinion leaders in the oncology field.
About
TriSalus Life Sciences, Inc., headquartered in Westminster, Colorado, is a pioneering immunotherapy company dedicated to transforming the treatment landscape for liver and pancreatic tumors. The company was founded with the vision of enhancing drug delivery to these difficult-to-treat cancers, leveraging innovative technologies to improve patient outcomes. TriSalus has developed two core systems: the TriNav Infusion System, designed for hepatic arterial infusion of liver tumors, and the Pancreatic Retrograde Venous Infusion System, tailored for pancreatic tumors. These systems are designed to overcome the challenges of delivering therapies effectively to these tumor types. Central to TriSalus's pipeline is SD-101, an investigational immunotherapeutic that utilizes the company's proprietary pressure-enabled drug delivery technology. SD-101 is being evaluated for a range of indications, including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. This broad application highlights the potential of SD-101 to address significant unmet needs across various cancer types. The company's focus on pressure-enabled drug delivery represents a unique approach in the field of immunotherapy, aiming to improve drug penetration and efficacy within the tumor microenvironment. With a dedicated team and a commitment to innovation, TriSalus Life Sciences is striving to make a meaningful difference in the lives of patients battling liver and pancreatic cancers.
What They Do
- Develops and commercializes immunotherapies for liver and pancreatic tumors.
- Offers the TriNav Infusion System for targeted drug delivery to liver tumors.
- Provides the Pancreatic Retrograde Venous Infusion System for pancreatic tumors.
- Develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery.
- Conducts clinical trials to evaluate the safety and efficacy of its therapies.
- Focuses on improving drug penetration and efficacy within the tumor microenvironment.
- Aims to transform the treatment landscape for challenging cancers.
Business Model
- Develops and patents innovative drug delivery systems and immunotherapies.
- Generates revenue through the sale of its TriNav Infusion System and Pancreatic Retrograde Venous Infusion System.
- Seeks regulatory approvals for its SD-101 immunotherapeutic to expand its product offerings.
- Potentially generates revenue through strategic partnerships and licensing agreements.
Industry Context
TriSalus Life Sciences operates within the medical device and immunotherapy sectors, targeting the specific niche of liver and pancreatic cancer treatments. The market for cancer therapies is substantial and growing, driven by an aging population and advancements in diagnostic technologies. The competitive landscape includes companies developing traditional chemotherapies, radiation therapies, and other immunotherapies. TriSalus differentiates itself through its pressure-enabled drug delivery technology, which aims to improve the efficacy of existing and novel cancer treatments. The global liver cancer therapeutics market is projected to reach billions of dollars by 2030, presenting a significant opportunity for TriSalus.
Key Customers
- Oncologists specializing in the treatment of liver and pancreatic cancers.
- Hospitals and cancer centers that offer advanced cancer therapies.
- Patients with liver and pancreatic tumors who are candidates for TriSalus's therapies.
- Pharmaceutical companies interested in collaborating on drug development and commercialization.
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $7M | -$2M | $-0.12 |
| Q4 2024 | $8M | -$10M | $-0.40 |
| Q1 2025 | $9M | -$10M | $-0.39 |
| Q2 2025 | $11M | -$8M | $-0.27 |
Source: Company filings
Chart & Info
Price Chart
TriSalus Life Sciences, Inc. (TLSI) stock price: $6.11 (+0.01, +0.16%)
Why Bull
- •Recent insider buying indicates confidence in the company's future, suggesting that executives believe in the potential for growth.
- •Community sentiment has shifted positively, with discussions highlighting innovative treatments that could position TriSalus as a leader in its field.
- •Recent partnerships have sparked optimism, showing that the company is actively expanding its reach and capabilities in the market.
- •Analysts have noted an increase in awareness and interest in the company's unique approach to cancer treatment, which could drive future demand.
Why Bear
- •Concerns over regulatory hurdles have emerged, with some investors worried about the timeline for product approvals affecting the company's growth prospects.
- •Recent social media discussions have revealed skepticism regarding the scalability of TriSalus's technology, raising doubts about its long-term viability.
- •Market perception remains cautious due to the competitive landscape, with other companies advancing in similar therapeutic areas, potentially overshadowing TriSalus.
- •Insider selling activity has also been noted, which may signal a lack of confidence among some executives regarding short-term performance.
Latest News
-
Earnings Scheduled For November 13, 2025
benzinga · Nov 13, 2025
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Sep 7, 2023
Technical Analysis
Rationale
AI-generated technical analysis for TLSI including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss TriSalus Life Sciences, Inc. (TLSI) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for TLSI.
Make a Prediction
Set your price target for TriSalus Life Sciences, Inc. (TLSI), choose a timeframe, and track your prediction accuracy.
Current price: $6.11
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TLSI.
Price Targets
Median: $10.50 (+71.8% from current price)
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 8/100
Revenue grew 59.0% YoY, showing strong top-line momentum well above industry average.
-
Gross Margin 10/100
Gross margin of 84.0% shows excellent pricing power and a strong competitive moat.
-
Operating Leverage 6/100
Revenue growth is driving operating leverage, meaning profits can grow faster than costs.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 10/100
Insiders bought +$1.79M net in recent filings, a strong confidence signal from those who know the company best.
-
Short Interest 10/100
Daily turnover of 1.34% indicates healthy liquidity with smooth entry/exit for investors.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates TLSI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does TriSalus Life Sciences, Inc. do?
TriSalus Life Sciences is an immunotherapy company focused on developing and commercializing innovative treatments for liver and pancreatic tumors. The company's core technology revolves around pressure-enabled drug delivery, which aims to improve the penetration and efficacy of therapies within the tumor microenvironment. They offer the TriNav Infusion System and the Pancreatic Retrograde Venous Infusion System, and are developing SD-101, an investigational immunotherapeutic. TriSalus seeks to transform the treatment landscape for these challenging cancers by enhancing drug delivery and improving patient outcomes.
Is TLSI stock a good buy?
TLSI stock presents a speculative investment opportunity with high potential upside and significant risks. The company's innovative pressure-enabled drug delivery technology and focus on underserved cancer markets are compelling. However, the negative P/E ratio of -5.17 and reliance on clinical trial success for SD-101 introduce considerable uncertainty. A positive outcome in upcoming clinical trials could drive significant stock appreciation, while failure could lead to substantial losses. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in TLSI.
What are the main risks for TLSI?
The main risks for TriSalus Life Sciences include the potential failure of SD-101 in clinical trials, which would significantly impact the company's pipeline and valuation. Competition from larger, more established pharmaceutical companies poses a threat. Regulatory hurdles and delays in obtaining approvals for new therapies could also impede progress. The company's current financial situation, characterized by a negative profit margin of -98.4%, raises concerns about its long-term sustainability. Dependence on key personnel and intellectual property also represents a risk factor.
Is TLSI a good stock to buy?
Whether TLSI is a suitable investment depends on your goals, risk tolerance, and time horizon. Evaluate TriSalus Life Sciences, Inc.'s revenue growth, profit margins, debt levels, and valuation relative to peers. This is not financial advice.
What is the TLSI MoonshotScore?
The MoonshotScore rates TLSI from 0 to 100 across growth potential, financial health, market momentum, and risk factors. Scores above 70 suggest strong potential, 50-70 moderate, and below 50 warrants caution. It is recalculated daily using the latest market data. This score is informational only.
How often is TLSI data updated?
TLSI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What do analysts say about TLSI?
Analyst coverage for TLSI includes consensus ratings (buy, hold, sell), 12-month price targets, and earnings estimates from major research firms. Key data points: consensus target price, number of covering analysts, recent upgrades or downgrades, and earnings beat/miss history. See the Analyst Consensus section on this page.
What are the risks of investing in TLSI?
Risk categories for TLSI include market risk, company-specific risk (management, competition), financial risk (debt, cash burn), and macroeconomic risk (rates, inflation). Beta above 1.0 indicates higher volatility than the S&P 500. Review the Risk Factors section on this page for details. All investments carry risk of loss.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available data as of 2026-02-08.
- Clinical trial outcomes for SD-101 are uncertain and could significantly impact the company's future.
- Market projections are based on industry reports and analyst estimates, which may vary.